Meeting
2024 ASCO Breakthrough
Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.
Authors
Xingliang Tan
Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China
Xingliang Tan , Zhicheng Liu , Qianghua Zhou , Kai Yao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Antibody Drug Conjugates
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 111)
DOI
10.1200/JCO.2024.42.23_suppl.111
Abstract #
111
Poster Bd #
H1
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Discordance of HER2 expression in distant metastatic tumors (MTs) versus primary tumors (PTs) in urothelial carcinoma (UC).
First Author: Claud Grigg
Poster
2013 Gastrointestinal Cancers Symposium
Differential HER2 expression in resected gastric cancer: Is there prognostic value?
First Author: Sarah Fisher
Poster
2024 ASCO Annual Meeting
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
First Author: Piotr Jan Wysocki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The distribution of human epidermal growth factor receptor 2 (HER2) expression and the efficacy and safety of treatments in HER2-expressing advanced or metastatic gastroesophageal cancer: A systematic literature review (SLR).
First Author: David Bing Zhen